Streetbeat News

ABVX

ABIVAX SA

https://www.abivax.com

Industry

Biotechnology

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

Open

6.54

Mkt cap

431M

Volume

325K

High

6.81

P/E Ratio

-1.82

52-wk high

17.02

Low

5.95

Div yield

N/A

52-wk low

5.50

Wall Street analysts have set a consensus price target for Abivax SA Sponsored ADR (ABVX) indicating a potential 360.5% upside. Despite skepticism about the effectiveness of such metrics, positive earnings estimate revisions suggest a possible near-term stock price increase.

Portfolio Pulse from

February 27, 2025 | 4:00 pm

Analysts predict a significant upside for Abivax SA Sponsored ADR (ABVX), with a mean price target suggesting a potential 427.9% increase. Despite the historical unreliability of such metrics, the consensus on raising earnings estimates supports a positive outlook.

Portfolio Pulse from

February 11, 2025 | 4:15 pm

Abivax SA Sponsored ADR (ABVX) has experienced a significant decline of 19.81% over the past four weeks, leading to it being technically oversold. This suggests a potential exhaustion of selling pressure. Additionally, Wall Street analysts have been revising earnings estimates higher, indicating a possible trend reversal for ABVX in the near term.

Portfolio Pulse from

January 30, 2025 | 3:45 pm

Abivax, a clinical-stage biotechnology company, has published its 2025 financial communications calendar. Key dates include the release of the 2024 Annual Business and Financial Report on March 24, 2025, Q1 Financial Results on June 2, 2025, the Annual General Meeting on June 6, 2025, Half-Year Financial Report on August 11, 2025, and Q3 Financial Results on December 15, 2025.

Portfolio Pulse from

January 28, 2025 | 7:45 am

Abivax will present seven abstracts on Obefazimod for ulcerative colitis at the 2025 European Crohn's and Colitis Organization Congress.

Portfolio Pulse from

January 23, 2025 | 9:15 pm

Abivax has reached 82% of its target enrollment in the Phase 3 ABTECT trial for obefazimod, a treatment for ulcerative colitis. The trial is expected to complete enrollment by Q2 2025.

Portfolio Pulse from

January 09, 2025 | 5:00 pm

Abivax SA, a biotechnology company listed on Euronext Paris and Nasdaq, announced a change in its Board of Directors. Dr. Philippe Pouletty resigned as director, effective December 31, 2024, due to his new role as Chairman and acting CEO of another company.

Portfolio Pulse from

December 23, 2024 | 9:30 pm

Abivax, a clinical-stage biotechnology company, released its key financial information for Q3 2024. The company is focused on developing therapeutics for chronic inflammatory diseases.

Portfolio Pulse from

November 14, 2024 | 9:15 pm

Abivax has enrolled the first patient in its Phase 2b trial, ENHANCE-CD, for the drug Obefazimod, aimed at treating Crohn's Disease.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 8:01 pm

Abivax has reported positive interim results for its drug Obefazimod, showing efficacy and safety in treating moderate to severe ulcerative colitis over a two-year period. The drug maintained clinical remission and was well-tolerated with no new safety concerns.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 7:08 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.